Every few months a new drug gets called a game changer. Most of the time that label is wrong. But retatrutide is different, and the data backs that up.
I have spent a lot of time going through the clinical trial results on this compound. What I found was that the numbers are unlike anything we have seen before in obesity medicine. That does not mean it is right for everyone. But if you are asking whether is retatrutide the best option currently in development, the honest answer is that it is the strongest candidate we have seen so far.
Here is what the research actually shows.
What Makes Retatrutide Different From Other GLP-1 Drugs?
Most GLP-1 drugs work on one receptor. semaglutide, for example, targets the GLP-1 receptor. That alone produces meaningful weight loss. Tirzepatide added a second receptor, GIP, and the results improved further.
Retatrutide goes one step further. It targets three receptors at the same time. GLP-1, GIP, and glucagon. This triple agonist approach is what separates it from everything else on the market right now.
Here is why that matters. Each receptor does something different in your body.
- GLP-1 reduces appetite and slows how fast food leaves your stomach
- GIP improves how your body handles insulin and fat storage
- Glucagon increases how much energy your body burns at rest
When you hit all three at once, you get appetite suppression, better metabolic function, and a higher resting metabolic rate. That combination is what drives the results we are seeing in trials.
Is Retatrutide Better Than Semaglutide for Weight Loss?
Yes, based on current trial data, retatrutide produces significantly more weight loss than semaglutide.
In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants taking the highest dose of retatrutide lost an average of 24.2 percent of their body weight over 48 weeks. That is roughly one in four kilograms gone for every four kilograms you carry.
Compare that to semaglutide. The STEP 1 trial showed an average weight loss of 14.9 percent over 68 weeks. Tirzepatide, which was already considered a major step forward, showed around 20 to 22 percent in the SURMOUNT-1 trial.
Retatrutide at its highest dose beat both of those numbers in a shorter timeframe.
What I found interesting in the data was that the dose response was very clear. Higher doses produced more weight loss, and the curve had not flattened out by the end of the trial. That suggests there may be even more room to push results further in Phase 3 studies.
How Much Weight Can You Lose With Retatrutide?
In the Phase 2 trial, participants on the 12mg dose lost an average of 24.2 percent of body weight in 48 weeks. Some participants lost significantly more than that.
To put that in real numbers, a person weighing 100kg could expect to lose around 24kg on average. That is approaching the results you would see from bariatric surgery, which typically produces 25 to 35 percent total body weight loss.
The lower doses still produced strong results. The 4mg group lost around 8.7 percent and the 8mg group lost around 17.3 percent. So even at conservative doses, the drug outperforms older GLP-1 medications.
One thing worth noting is that these results came with lifestyle intervention included. Participants received diet and exercise counseling alongside the medication. That matters because the drug works best when paired with real behavior change, not as a standalone fix.
Is Retatrutide FDA-Approved?
No. As of 2025, retatrutide is not FDA-approved.
It completed Phase 2 trials with strong results and Eli Lilly, the company developing it, has moved into Phase 3 trials. Phase 3 is the large scale human trial required before a drug can be submitted for FDA approval.
Phase 3 trials typically take two to four years to complete. If those results hold up, and there is good reason to think they will, retatrutide could reach FDA approval somewhere around 2026 to 2027.
Until then, it is not available as a prescription medication in the United States, Australia, or most other countries. Anyone claiming to sell approved retatrutide right now is not selling what they say they are.
What Are the Side Effects of Retatrutide?
The side effect profile looks similar to other GLP-1 drugs, which is both reassuring and worth paying attention to.
In the Phase 2 trial, the most common side effects were gastrointestinal. Nausea, vomiting, diarrhea, and constipation were reported most frequently. These effects were most common when doses were increased and tended to reduce over time as the body adjusted.
Here is the breakdown from the trial data:
- Nausea affected around 40 to 60 percent of participants at higher doses
- Vomiting affected around 20 to 30 percent
- Diarrhea and constipation were reported in roughly 15 to 25 percent
- Most side effects were rated mild to moderate in severity
Serious adverse events were low. The trial did not show significant cardiovascular signals, which is important given that the glucagon receptor component raises some theoretical concerns about heart rate. Heart rate did increase slightly in participants, which is something Phase 3 trials will monitor closely.
In my experience reviewing GLP-1 trial data, the nausea profile here is consistent with what we see across the class. The slow dose escalation protocol used in the trial is specifically designed to reduce that burden.
Is Retatrutide Safe for Long-Term Use?
We do not have long-term safety data yet. That is the honest answer.
Phase 2 trials run for under a year. We do not have two, five, or ten year data on retatrutide. What we do have is a reasonable basis for confidence based on the safety profile of related drugs.
Semaglutide has been used for years and has a well-established long-term safety record. The SUSTAIN and STEP trial programs, along with real world use in millions of patients, have not shown major long-term safety concerns. Tirzepatide is following a similar trajectory.
Retatrutide shares the same receptor targets as those drugs, plus the glucagon component. The glucagon piece is the main unknown for long-term use. Glucagon receptor activation can affect liver function and bone density in animal models. Whether that translates to humans at therapeutic doses is something Phase 3 will need to answer.
What I found reassuring in the Phase 2 data was that liver enzymes and bone markers did not show concerning changes over the 48 week period. But 48 weeks is not long enough to draw firm conclusions about decade-long use.
If you are considering any GLP-1 class drug for long-term weight management, the current evidence supports their use under medical supervision. The risk-benefit calculation for people with obesity-related health conditions generally favors treatment.
Who Is Retatrutide Actually For?
Based on the trial population and the mechanism of action, retatrutide is being developed for adults with obesity or overweight with at least one weight-related health condition. That is the same target population as semaglutide and tirzepatide.
The Phase 2 trial enrolled participants with a BMI of 27 or higher. The average BMI was around 37. These were people carrying significant excess weight, not people looking to lose the last five kilograms.
The drug is not a performance tool or a shortcut for people who are already at a healthy weight. The risk-benefit profile only makes sense when there is meaningful metabolic risk to address.
That said, the results at lower doses are still strong enough that the approved indication may eventually extend to lower BMI ranges, particularly if cardiovascular outcome data is positive.
Three Things Most People Get Wrong About Retatrutide
First, people assume it works without lifestyle change. It does not. The trial results came with diet and exercise support built in. The drug amplifies the results of behavior change, it does not replace it. When I looked at the data, the participants who did best were the ones who combined the medication with real changes to how they ate and moved.
Second, people think more drug means more results indefinitely. The dose response curve does flatten. There is a ceiling. And higher doses come with more side effects. The optimal dose is the one that produces the best results with the least side effect burden, not the highest dose available.
Third, people treat stopping the drug as a failure. Weight regain after stopping GLP-1 drugs is well documented. The STEP 4 trial showed that people who stopped semaglutide regained about two thirds of their lost weight within a year. Retatrutide will likely show similar patterns. This is not a character flaw. It reflects the biology of obesity as a chronic condition that requires ongoing management.
FAQ
Is retatrutide available to buy right now?
No. Retatrutide is in Phase 3 clinical trials and is not approved for prescription use anywhere in the world as of 2025. Any product being sold as retatrutide is not the real compound.
How does retatrutide compare to tirzepatide?
Retatrutide produced higher average weight loss in Phase 2 trials than tirzepatide produced in its Phase 3 trials. Tirzepatide showed around 20 to 22 percent weight loss. Retatrutide showed up to 24.2 percent. Direct head-to-head trials have not been completed yet.
Will retatrutide be approved faster because of the strong results?
Strong Phase 2 results can support faster Phase 3 enrollment and potentially priority review status from the FDA. But the regulatory process still requires full Phase 3 completion. There are no shortcuts that bypass that requirement.
Can you use retatrutide if you have type 2 diabetes?
The Phase 2 trial focused on obesity without diabetes. Separate trials are evaluating retatrutide in people with type 2 diabetes. Early data looks promising for blood sugar control as well as weight loss, but the diabetes indication will require its own approval pathway.
What happens to muscle mass on retatrutide?
This is an important question. GLP-1 drugs can cause loss of lean muscle mass alongside fat loss. The Phase 2 trial did not report detailed body composition data. Phase 3 trials are expected to include DEXA scan measurements to track this. Resistance training during treatment is strongly recommended to preserve muscle mass regardless of which GLP-1 drug you use.
The Bottom Line
Retatrutide produces more weight loss than any approved drug in its class. The mechanism makes sense, the Phase 2 data is strong, and the side effect profile is manageable. It is not approved yet and long-term safety data does not exist.
If you are managing your weight right now, the tools available today, including semaglutide, tirzepatide, and structured lifestyle programs, are effective. Waiting for retatrutide is not a strategy. Working with a qualified coach or clinician to build the habits that make any of these tools work better is.
The drug does not do the work. It creates the conditions for the work to happen. That distinction matters more than which molecule you are using.
